Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol® in Adults with Moderate to Severe Dry Eye Disease

HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq announced positive Phase 2 results evaluating CyclASol in patients with moderate to severe dry eye disease, meeting its primary endpoint with an early onset of action.